Autolus Therapeutics (AUTL) Shares Outstanding (Diluted Average) (2020 - 2025)

Autolus Therapeutics (AUTL) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $266.1 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Diluted Average) rose 4.32% year-over-year to $266.1 million; the trailing twelve-month figure through Jun 2025 stood at $266.1 million (up 4.32% YoY), and the FY2024 full-year result was $255.2 million, up 46.69% from the prior year.
• Shares Outstanding (Diluted Average) for Q2 2025 stood at $266.1 million, roughly flat from $266.1 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $266.1 million in Q2 2025 and bottomed at $62.4 million in Q1 2021.
• The 5-year median for Shares Outstanding (Diluted Average) is $173.9 million (2023), against an average of $163.9 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Diluted Average) surged 5805807.95%; it then gained 4.32% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $72.9 million in 2021, then surged by 30.31% to $95.0 million in 2022, then jumped by 83.11% to $173.9 million in 2023, then surged by 46.69% to $255.2 million in 2024, then climbed by 4.3% to $266.1 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $266.1 million (Q2 2025), $266.1 million (Q1 2025), and $255.2 million (Q4 2024), per Business Quant data.

Peer Comparison